This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
=== Alternative treatments === Over 50% of people with MS may use complementary and alternative medicine, although percentages vary depending on how alternative medicine is defined. Regarding the characteristics of users, they are more frequently women, have had MS for a longer time, tend to be more disabled and have lower levels of satisfaction with conventional healthcare. The evidence for the effectiveness for such treatments in most cases is weak or absent. Treatments of unproven benefit used by people with MS include dietary supplementation and regimens, vitamin D, relaxation techniques such as yoga, herbal medicine (including medical cannabis), hyperbaric oxygen therapy, self-infection with hookworms, reflexology, acupuncture, and mindfulness. Evidence suggests vitamin D supplementation, irrespective of the form and dose, provides no benefit for people with MS; this includes for measures such as relapse recurrence, disability, and MRI lesions while effects on health‐related quality of life and fatigue are unclear. There is insufficient evidence supporting high-dose biotin and some evidence for increased disease activity and higher risk of relapse with its use.
==== Charge site-initiated cleavage ==== The driving force of charge site-initiated fragmentation is the inductive effect of the charge site in radical cations. The electrons from the bond adjacent to the charge-bearing atom migrate to that atom, neutralizing the original charge and causing it to move to a different site. This term is also called inductive cleavage and is an example of heterolytic bond cleavage.
Although commercial refrigeration quickly progressed, it had limitations that prevented it from moving into the household. First, most refrigerators were far too large. Some of the commercial units being used in 1910 weighed between five and two hundred tons. Second, commercial refrigerators were expensive to produce, purchase, and maintain. Lastly, these refrigerators were unsafe. It was not uncommon for commercial refrigerators to catch fire, explode, or leak toxic gases. Refrigeration did not become a household technology until these three challenges were overcome.
Raisins – are dried grapes produced in many regions of the world, and may be eaten raw or used in cooking, baking, and brewing. A ristra – is an arrangement of drying chili pepper pods, used to dry them and also for decoration.
Sources: en.wikipedia.org
peroxisome A small membrane-bound organelle found in many eukaryotic cells which specializes in carrying out oxidative reactions with various enzyme peroxidases and catalase, generally to mitigate damage from reactive oxygen species but also as a participant in various metabolic pathways such as beta-oxidation of fatty acids.
=== Addition to alkenes and alkynes === The Hg2+ center binds to alkenes, inducing the addition of hydroxide and alkoxide. For example, treatment of methyl acrylate with mercuric acetate in methanol gives an α-mercuri ester:
== Debonding and loss == In 1953, sociologist Diane Vaughan proposed an uncoupling theory. It states that during the dynamics of relationship breakup, there exists a "turning point," only noted in hindsight, followed by a transition period in which one partner unconsciously knows the relationship is going to end, but holds on to it for an extended period, sometimes for a number of years. When a person to which one has become bonded is lost, a grief response may occur. Grief is the process of accepting the loss and adjusting to the changed situation. Grief may take longer than the initial development of the bond. The grief process varies with culture.
== Sources == Bingham, Jonathan Brewster (1953). Shirt-Sleeve Diplomacy: Point 4 in Action. John Day & Co. Brown, William Adams Jr.; Opie, Redvers (1953). American Foreign Assistance. Washington, DC: The Brookings Institution. Butterfield, Samuel Hale (2004). U.S. Development Aid – An Historic First: Achievements and Failures in the Twentieth Century. Westport, CN: Praeger. ISBN 0-313-31910-3. Glick, Philip M. (1957). The Administration of Technical Assistance: Growth in the Americas. Chicago: University of Chicago Press. Haviland, H. Field (1958). "Foreign Aid and the Policy Process: 1957". The American Political Science Review. 52 (3): 689–724. doi:10.2307/1951900. JSTOR 1951900. S2CID 144564474. Hayes, Samuel J., ed. (1971). The Beginnings of American Aid to Southeast Asia: The Griffin Mission of 1950. Lexington, MA: Heath Lexington Books. Jolly, Richard; Emmerji, Louis; Ghai, Dharam; Lapeyre, Frederic (2004). UN Contributions to Development Thinking and Practice. Bloomington: Indiana University Press. Kaufman, B. Ira (1982). Trade and aid : Eisenhower's foreign economic policy, 1953–1961. Baltimore, MD: Johns Hopkins University Press. p. 82. ISBN 978-0-8018-2623-8. Nowels, Larry Q. (February 1987). Economic Security Assistance As a Tool of American Foreign Policy: The Current Dilemma and Future Options (PDF) (Report). National War College. Archived from the original (PDF) on 2017-10-11. Retrieved 2017-06-20 – via Development Experience Clearinghouse. Ruttan, Vernon W. (1996). United States Development Assistance Policy: The Domestic Politics of Foreign Economic Aid.
== Further reading == Genck, Wayne (7 November 2010). "Make The Most of Antisolvent Crystallization". Chemical Processing. Putman Media. Retrieved 12 June 2025. Sheehan, David (2009). Physical Biochemistry: Principles and Applications. John Wiley & Sons. p. 285. ISBN 978-0-470-85602-4. Miller, S A; Dykes, D D; Polesky, H F (11 February 1988). "A simple salting out procedure for extracting DNA from human nucleated cells". Nucleic Acids Research. 16 (3): 1215. CiteSeerX 10.1.1.941.1917. doi:10.1093/nar/16.3.1215. PMC 334765. PMID 3344216. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) McKay, H. A. C. (1 January 1953). "Activities and activity coefficients in ternary systems". Transactions of the Faraday Society. 49: 237–242. doi:10.1039/TF9534900237.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.